CA3189752A1 - Methods and processes for non-invasive assessment of genetic variations - Google Patents
Methods and processes for non-invasive assessment of genetic variationsInfo
- Publication number
- CA3189752A1 CA3189752A1 CA3189752A CA3189752A CA3189752A1 CA 3189752 A1 CA3189752 A1 CA 3189752A1 CA 3189752 A CA3189752 A CA 3189752A CA 3189752 A CA3189752 A CA 3189752A CA 3189752 A1 CA3189752 A1 CA 3189752A1
- Authority
- CA
- Canada
- Prior art keywords
- chromosome
- nucleic acid
- portions
- candidate segment
- counts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 691
- 230000007614 genetic variation Effects 0.000 title claims abstract description 217
- 230000008569 process Effects 0.000 claims abstract description 226
- 238000004458 analytical method Methods 0.000 claims abstract description 136
- 230000011218 segmentation Effects 0.000 claims abstract description 52
- 230000001605 fetal effect Effects 0.000 claims description 549
- 150000007523 nucleic acids Chemical group 0.000 claims description 506
- 210000000349 chromosome Anatomy 0.000 claims description 474
- 102000039446 nucleic acids Human genes 0.000 claims description 453
- 108020004707 nucleic acids Proteins 0.000 claims description 453
- 238000012360 testing method Methods 0.000 claims description 281
- 208000036878 aneuploidy Diseases 0.000 claims description 152
- 231100001075 aneuploidy Toxicity 0.000 claims description 145
- 238000010606 normalization Methods 0.000 claims description 128
- 238000000354 decomposition reaction Methods 0.000 claims description 107
- 210000003754 fetus Anatomy 0.000 claims description 107
- 238000012163 sequencing technique Methods 0.000 claims description 104
- 238000009826 distribution Methods 0.000 claims description 83
- 238000009877 rendering Methods 0.000 claims description 73
- 238000011002 quantification Methods 0.000 claims description 70
- 239000002131 composite material Substances 0.000 claims description 61
- 208000037280 Trisomy Diseases 0.000 claims description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 15
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 13
- 238000013507 mapping Methods 0.000 claims description 12
- 208000030454 monosomy Diseases 0.000 claims description 12
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 7
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 7
- 229940104302 cytosine Drugs 0.000 claims description 7
- 238000007517 polishing process Methods 0.000 claims description 6
- 238000005315 distribution function Methods 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 238000003708 edge detection Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 373
- 230000008774 maternal effect Effects 0.000 description 186
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 177
- 238000012217 deletion Methods 0.000 description 110
- 239000002585 base Substances 0.000 description 108
- 230000037430 deletion Effects 0.000 description 103
- 125000003729 nucleotide group Chemical group 0.000 description 87
- 102000053602 DNA Human genes 0.000 description 85
- 108020004414 DNA Proteins 0.000 description 85
- 239000012634 fragment Substances 0.000 description 83
- 239000002773 nucleotide Substances 0.000 description 81
- 238000012545 processing Methods 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 59
- 230000000670 limiting effect Effects 0.000 description 56
- 238000012417 linear regression Methods 0.000 description 55
- 238000001914 filtration Methods 0.000 description 54
- 230000003321 amplification Effects 0.000 description 50
- 238000013459 approach Methods 0.000 description 50
- 238000003199 nucleic acid amplification method Methods 0.000 description 50
- 210000004369 blood Anatomy 0.000 description 43
- 239000008280 blood Substances 0.000 description 43
- 230000006870 function Effects 0.000 description 39
- 238000003780 insertion Methods 0.000 description 39
- 238000000513 principal component analysis Methods 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 230000002068 genetic effect Effects 0.000 description 36
- 230000037431 insertion Effects 0.000 description 36
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 30
- 238000005516 engineering process Methods 0.000 description 29
- 230000011987 methylation Effects 0.000 description 28
- 238000007069 methylation reaction Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 108091034117 Oligonucleotide Proteins 0.000 description 25
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 24
- 241000894007 species Species 0.000 description 23
- 108700028369 Alleles Proteins 0.000 description 22
- 238000003776 cleavage reaction Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 238000012549 training Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229920002477 rna polymer Polymers 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 19
- 210000003765 sex chromosome Anatomy 0.000 description 19
- 238000010200 validation analysis Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 18
- 230000007017 scission Effects 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 238000000926 separation method Methods 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 16
- 208000031404 Chromosome Aberrations Diseases 0.000 description 15
- 201000010374 Down Syndrome Diseases 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 206010007559 Cardiac failure congestive Diseases 0.000 description 14
- 238000012937 correction Methods 0.000 description 14
- 238000009795 derivation Methods 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 239000013074 reference sample Substances 0.000 description 14
- 239000007790 solid phase Substances 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000035935 pregnancy Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000005498 polishing Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 206010044688 Trisomy 21 Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- -1 skin Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000000638 solvent extraction Methods 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 210000002593 Y chromosome Anatomy 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 206010068052 Mosaicism Diseases 0.000 description 9
- 238000012896 Statistical algorithm Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000007906 compression Methods 0.000 description 9
- 238000002790 cross-validation Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 238000000611 regression analysis Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000031639 Chromosome Deletion Diseases 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 230000003322 aneuploid effect Effects 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009499 grossing Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000005192 partition Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000001766 X chromosome Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 108010047956 Nucleosomes Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 208000026928 Turner syndrome Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000873 masking effect Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 210000001623 nucleosome Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 238000012935 Averaging Methods 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 4
- 201000009928 Patau syndrome Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 206010044686 Trisomy 13 Diseases 0.000 description 4
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 108091092328 cellular RNA Proteins 0.000 description 4
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 231100000005 chromosome aberration Toxicity 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000003066 decision tree Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000007847 digital PCR Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000012886 linear function Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000007781 pre-processing Methods 0.000 description 4
- 238000010379 pull-down assay Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010053884 trisomy 18 Diseases 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 201000006360 Edwards syndrome Diseases 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 230000005669 field effect Effects 0.000 description 3
- 238000007672 fourth generation sequencing Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 208000023463 mandibuloacral dysplasia Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000000120 microwave digestion Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 208000026485 trisomy X Diseases 0.000 description 3
- 238000009827 uniform distribution Methods 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 208000026817 47,XYY syndrome Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 238000001159 Fisher's combined probability test Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000001430 Omnibus test Methods 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000004006 camptodactyly-arthropathy-coxa vara-pericarditis syndrome Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 108091092240 circulating cell-free DNA Proteins 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010252 digital analysis Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 208000012978 nondisjunction Diseases 0.000 description 2
- 238000013488 ordinary least square regression Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 208000036897 pentasomy Diseases 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 102000005963 steroid binding proteins Human genes 0.000 description 2
- 108020003178 steroid binding proteins Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 208000011908 tetrasomy Diseases 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CJYDNDLQIIGSTH-UHFFFAOYSA-N 1-(3,5,7-trinitro-1,3,5,7-tetrazocan-1-yl)ethanone Chemical compound CC(=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 CJYDNDLQIIGSTH-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000024341 Aicardi syndrome Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
- 208000001454 Anhidrotic Ectodermal Dysplasia 1 Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102100023086 Anosmin-1 Human genes 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000018311 Autosomal trisomy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000025480 CHILD syndrome Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000003728 Centronuclear myopathy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 201000009744 Charcot-Marie-Tooth disease X-linked recessive 2 Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000033810 Choroidal dystrophy Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010452 Congenital ectodermal dysplasia Diseases 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000011518 Danon disease Diseases 0.000 description 1
- 208000024940 Dent disease Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 208000010255 Familial Hypoadrenocorticism Diseases 0.000 description 1
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 201000008251 Focal dermal hypoplasia Diseases 0.000 description 1
- 206010064041 Foetal chromosome abnormality Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 1
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 1
- 208000032003 Glycogen storage disease due to glucose-6-phosphatase deficiency Diseases 0.000 description 1
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101150007028 HTRA1 gene Proteins 0.000 description 1
- 241000691979 Halcyon Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001050039 Homo sapiens Anosmin-1 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 1
- 201000004029 Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 208000027646 Infantile-onset X-linked spinal muscular atrophy Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 208000014779 Keipert syndrome Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 201000002961 MASA syndrome Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000021964 McLeod neuroacanthocytosis syndrome Diseases 0.000 description 1
- 208000026486 McLeod syndrome Diseases 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 208000016679 Monosomy X Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 201000007908 Ocular Albinism Diseases 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 description 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 description 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 description 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000031486 Properdin deficiency Diseases 0.000 description 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000019594 Smith-Fineman-Myers syndrome Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032978 Structural Congenital Myopathies Diseases 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102100028709 Thyroxine-binding globulin Human genes 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010063092 Trisomy 12 Diseases 0.000 description 1
- 206010053871 Trisomy 8 Diseases 0.000 description 1
- 208000031655 Uniparental Disomy Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 208000031691 X-linked Charcot-Marie-Tooth disease type 2 Diseases 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 201000004175 X-linked endothelial corneal dystrophy Diseases 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 208000031878 X-linked hypophosphatemia Diseases 0.000 description 1
- 208000001001 X-linked ichthyosis Diseases 0.000 description 1
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- 208000006756 X-linked sideroblastic anemia Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- 208000014914 X-linked spinal muscular atrophy 2 Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 238000001801 Z-test Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000012884 algebraic function Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000002439 alpha thalassemia-intellectual disability syndrome type 1 Diseases 0.000 description 1
- 201000002394 amelogenesis imperfecta type 1E Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013144 data compression Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000004541 glycogen storage disease I Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 description 1
- 208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 description 1
- 208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 102000031635 methyl-CpG binding proteins Human genes 0.000 description 1
- 108091009877 methyl-CpG binding proteins Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- 238000003062 neural network model Methods 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000007064 occipital horn syndrome Diseases 0.000 description 1
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000012898 one-sample t-test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 description 1
- 201000003455 orofaciodigital syndrome I Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 101800002712 p27 Proteins 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000013180 random effects model Methods 0.000 description 1
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 201000007245 sideroblastic anemia 1 Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 108700010045 sry Genes Proteins 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000001856 syndromic X-linked intellectual disability Siderius type Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000034298 trisomy chromosome 8 Diseases 0.000 description 1
- 238000012176 true single molecule sequencing Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827385P | 2013-05-24 | 2013-05-24 | |
| US61/827,385 | 2013-05-24 | ||
| CA2910205A CA2910205C (en) | 2013-05-24 | 2014-05-23 | Methods and processes for non-invasive assessment of genetic variations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2910205A Division CA2910205C (en) | 2013-05-24 | 2014-05-23 | Methods and processes for non-invasive assessment of genetic variations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3189752A1 true CA3189752A1 (en) | 2014-11-27 |
Family
ID=51023082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3189752A Pending CA3189752A1 (en) | 2013-05-24 | 2014-05-23 | Methods and processes for non-invasive assessment of genetic variations |
| CA2910205A Active CA2910205C (en) | 2013-05-24 | 2014-05-23 | Methods and processes for non-invasive assessment of genetic variations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2910205A Active CA2910205C (en) | 2013-05-24 | 2014-05-23 | Methods and processes for non-invasive assessment of genetic variations |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10699800B2 (enExample) |
| EP (3) | EP4604127A3 (enExample) |
| JP (2) | JP6561046B2 (enExample) |
| KR (4) | KR102665592B1 (enExample) |
| CN (2) | CN112575075B (enExample) |
| AU (3) | AU2014268377B2 (enExample) |
| CA (2) | CA3189752A1 (enExample) |
| IL (4) | IL300163B2 (enExample) |
| WO (1) | WO2014190286A2 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140235474A1 (en) | 2011-06-24 | 2014-08-21 | Sequenom, Inc. | Methods and processes for non invasive assessment of a genetic variation |
| US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
| US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2850785C (en) | 2011-10-06 | 2022-12-13 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2861856C (en) | 2012-01-20 | 2020-06-02 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20130309666A1 (en) | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3597774A1 (en) | 2013-03-13 | 2020-01-22 | Sequenom, Inc. | Primers for dna methylation analysis |
| EP4187543A1 (en) | 2013-04-03 | 2023-05-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2014190286A2 (en) | 2013-05-24 | 2014-11-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3011051B1 (en) * | 2013-06-21 | 2019-01-30 | Sequenom, Inc. | Method for non-invasive assessment of genetic variations |
| JP2016530876A (ja) * | 2013-06-28 | 2016-10-06 | ライフ テクノロジーズ コーポレーション | データ品質を可視化するための方法及びシステム |
| BR112016007401B1 (pt) | 2013-10-04 | 2023-04-11 | Sequenom, Inc. | Método para determinar a presença ou ausência de uma aneuploidia cromossômica em uma amostra |
| EP3495496B1 (en) | 2013-10-07 | 2020-11-25 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
| EP3117011B1 (en) | 2014-03-13 | 2020-05-06 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20150347676A1 (en) | 2014-05-30 | 2015-12-03 | Sequenom, Inc. | Chromosome representation determinations |
| US9118714B1 (en) * | 2014-07-23 | 2015-08-25 | Lookingglass Cyber Solutions, Inc. | Apparatuses, methods and systems for a cyber threat visualization and editing user interface |
| US20170211143A1 (en) * | 2014-07-25 | 2017-07-27 | University Of Washington | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same |
| WO2016019042A1 (en) | 2014-07-30 | 2016-02-04 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3204512B1 (en) | 2014-10-10 | 2020-05-06 | Sequenom, Inc. | Methods for partitioning of genomic sequences |
| EP3240909B1 (en) * | 2014-10-17 | 2020-10-14 | Good Start Genetics, Inc. | Pre-implantation genetic screening and aneuploidy detection |
| US10319463B2 (en) | 2015-01-23 | 2019-06-11 | The Chinese University Of Hong Kong | Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations |
| US11868851B2 (en) * | 2015-03-11 | 2024-01-09 | Symphonyai Sensa Llc | Systems and methods for predicting outcomes using a prediction learning model |
| BE1023267B1 (nl) * | 2015-07-13 | 2017-01-17 | Cartagenia N.V. | Werkwijze voor het analyseren van kopienummervariatie bij de detectie van kanker |
| BE1023266B1 (nl) * | 2015-07-13 | 2017-01-17 | Cartagenia N.V. | Systeem en methodologie voor de analyse van genomische gegevens die zijn verkregen van een onderwerp |
| EP3118324A1 (en) * | 2015-07-13 | 2017-01-18 | Cartagenia N.V. | Method for analyzing copy number variation in the detection of cancer |
| KR101817785B1 (ko) * | 2015-08-06 | 2018-01-11 | 이원다이애그노믹스(주) | 다양한 플랫폼에서 태아의 성별과 성염색체 이상을 구분할 수 있는 새로운 방법 |
| WO2017051996A1 (ko) * | 2015-09-24 | 2017-03-30 | 에스케이텔레콤 주식회사 | 비침습적 태아 염색체 이수성 판별 방법 |
| KR101817180B1 (ko) * | 2016-01-20 | 2018-01-10 | 이원다이애그노믹스(주) | 염색체 이상 판단 방법 |
| CN106053066A (zh) * | 2016-05-23 | 2016-10-26 | 华东交通大学 | 基于经验模态分解和逻辑回归的滚动轴承性能退化评估方法 |
| EP4043581A1 (en) | 2016-05-27 | 2022-08-17 | Sequenom, Inc. | Method for generating a paralog assay system |
| EP3491560A1 (en) | 2016-07-27 | 2019-06-05 | Sequenom, Inc. | Genetic copy number alteration classifications |
| CA3030894A1 (en) | 2016-07-27 | 2018-02-01 | Sequenom, Inc. | Methods for non-invasive assessment of genomic instability |
| US10650621B1 (en) | 2016-09-13 | 2020-05-12 | Iocurrents, Inc. | Interfacing with a vehicular controller area network |
| WO2018064486A1 (en) | 2016-09-29 | 2018-04-05 | Counsyl, Inc. | Noninvasive prenatal screening using dynamic iterative depth optimization |
| KR101907650B1 (ko) | 2016-11-24 | 2018-10-12 | 에스케이텔레콤 주식회사 | 비침습적 태아 염색체 이수성 판별 방법 |
| CN106845154B (zh) * | 2016-12-29 | 2022-04-08 | 浙江安诺优达生物科技有限公司 | 一种用于ffpe样本拷贝数变异检测的装置 |
| EP3571615B1 (en) | 2017-01-20 | 2024-01-24 | Sequenom, Inc. | Methods for non-invasive assessment of genetic alterations |
| WO2018136881A1 (en) | 2017-01-20 | 2018-07-26 | Sequenom, Inc. | Sequencing adapter manufacture and use |
| CA3049457C (en) | 2017-01-20 | 2023-05-16 | Sequenom, Inc. | Methods for non-invasive assessment of copy number alterations |
| CA3207879A1 (en) * | 2017-01-24 | 2018-08-02 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
| CN106778069B (zh) * | 2017-02-17 | 2020-02-14 | 广州精科医学检验所有限公司 | 确定胎儿染色体中微缺失微重复的方法及设备 |
| EP3596233B1 (en) | 2017-03-17 | 2022-05-18 | Sequenom, Inc. | Methods and processes for assessment of genetic mosaicism |
| SK862017A3 (sk) | 2017-08-24 | 2020-05-04 | Grendar Marian Doc Mgr Phd | Spôsob použitia fetálnej frakcie a chromozómovej reprezentácie pri určovaní aneuploidného stavu v neinvazívnom prenatálnom testovaní |
| KR102031841B1 (ko) | 2017-12-22 | 2019-10-15 | 테라젠지놈케어 주식회사 | 모체 시료 중 태아 분획을 결정하는 방법 |
| KR102029393B1 (ko) * | 2018-01-11 | 2019-10-07 | 주식회사 녹십자지놈 | 무세포 dna를 포함하는 샘플에서 순환 종양 dna를 검출하는 방법 및 그 용도 |
| IT201800005623A1 (it) * | 2018-05-23 | 2019-11-23 | Metodo per la determinazione della probabilità del rischio di anomalie cromosomiche e genetiche da dna libero di origine fetale | |
| CN110737006B (zh) * | 2018-07-20 | 2023-05-02 | 菜鸟智能物流控股有限公司 | 轨迹去噪的处理方法、装置以及电子设备 |
| US11940978B2 (en) * | 2018-09-19 | 2024-03-26 | International Business Machines Corporation | Distributed platform for computation and trusted validation |
| CN109447402B (zh) * | 2018-09-19 | 2022-02-22 | 语联网（武汉）信息技术有限公司 | 稿件基因的选取方法、装置与电子设备 |
| EP3856930A4 (en) * | 2018-09-24 | 2022-11-09 | Tempus Labs, Inc. | METHODS FOR NORMALIZATION AND CORRECTION OF RNA EXPRESSION DATA |
| CN109872783B (zh) * | 2018-12-28 | 2022-11-29 | 金力 | 一种基于大数据的糖尿病文献信息标准数据库集分析方法 |
| CN109709391B (zh) * | 2019-01-14 | 2021-02-02 | 江苏盛德电子仪表有限公司 | 一种带有高速载波通讯模块的智能电表及其通信系统 |
| KR102381252B1 (ko) * | 2019-02-19 | 2022-04-01 | 주식회사 녹십자지놈 | 혈중 무세포 dna 기반 간암 치료 예후예측 방법 |
| WO2020169635A1 (en) | 2019-02-20 | 2020-08-27 | Grendar Marian | Method for determining the uncertainty of the degree of placental mosaicism of a sample in non-invasive prenatal screening |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CA3115513A1 (en) * | 2019-06-03 | 2020-12-10 | Illumina, Inc. | Limit of detection based quality control metric |
| SG10201905438RA (en) * | 2019-06-14 | 2021-01-28 | Hui Qi Low | System and method for conducting trait assessment |
| CN114402392A (zh) * | 2019-06-21 | 2022-04-26 | 酷博尔外科器械有限公司 | 使用单核苷酸变异密度验证人类胚胎中拷贝数变异的系统和方法 |
| JP7333838B2 (ja) | 2019-06-21 | 2023-08-25 | クーパーサージカル・インコーポレイテッド | 胚における遺伝パターンを決定するためのシステム、コンピュータプログラム及び方法 |
| US11403641B2 (en) * | 2019-06-28 | 2022-08-02 | Paypal, Inc. | Transactional probability analysis on radial time representation |
| CN111027166B (zh) * | 2019-07-30 | 2024-06-07 | 天津大学 | 艇位周边海域海洋要素快速分析方法 |
| CN110457906B (zh) * | 2019-08-15 | 2023-03-31 | 国家电网公司华东分部 | 一种网络安全事件智能告警方法 |
| US20240395357A1 (en) | 2019-10-31 | 2024-11-28 | Sequenom, Inc. | Application of mosaicism ratio in multifetal gestations and personalized risk assessment |
| US11853450B2 (en) * | 2019-11-05 | 2023-12-26 | Saudi Arabian Oil Company | Detection of web application anomalies using machine learning |
| WO2021115906A1 (en) * | 2019-12-12 | 2021-06-17 | Koninklijke Philips N.V. | Method and system for determining a cnv profile for a tumor using sparse whole genome sequencing |
| CA3179883A1 (en) | 2020-12-02 | 2022-06-09 | Illumina Software, Inc. | System and method for detection of genetic alterations |
| TWI791347B (zh) * | 2020-12-11 | 2023-02-01 | 酷氏基因生物科技股份有限公司 | 一種用於評估胚胎植入成功率的預測方法 |
| WO2022140579A1 (en) * | 2020-12-24 | 2022-06-30 | Progenity, Inc. | Methods of preparing assays, systems, and compositions for determining fetal fraction |
| CN112906250B (zh) * | 2021-04-09 | 2022-05-31 | 吉林大学 | 一种复杂系统模块分类方法 |
| EP4396822A1 (en) * | 2021-09-03 | 2024-07-10 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Methods and devices for non-invasive prenatal testing |
| KR102704709B1 (ko) * | 2021-11-24 | 2024-09-10 | 지놈케어 주식회사 | 가상 데이터에 기반한 태아의 염색체이수성을 검출하는 방법 |
| CN119256095A (zh) * | 2022-03-24 | 2025-01-03 | 生物辐射实验室股份有限公司 | 使用数字试验测定核酸片段群体大小的方法和系统 |
| CN114563834B (zh) * | 2022-04-27 | 2022-07-26 | 知一航宇(北京)科技有限公司 | 一种数值预报产品解释应用方法及系统 |
| KR102470337B1 (ko) * | 2022-05-18 | 2022-11-25 | 주식회사 쓰리빌리언 | 변이 접합성 판별 시스템 |
| KR20240017305A (ko) | 2022-07-29 | 2024-02-07 | 황지영 | 분자생물학 마커를 이용한 크레스티드 게코 도마뱀의 성별 판별 방법 |
| CN115132271B (zh) * | 2022-09-01 | 2023-07-04 | 北京中仪康卫医疗器械有限公司 | 一种基于批次内校正的cnv检测方法 |
| CN116050876A (zh) * | 2022-11-18 | 2023-05-02 | 苏州大学 | 一种生态系统文化服务潜在供应评价及分布的分析方法 |
| CN115983102B (zh) * | 2022-12-08 | 2025-10-10 | 北京工业大学 | 一种基于空间网格化聚类的供水管道优化改造的方法 |
| WO2024137407A1 (en) * | 2022-12-21 | 2024-06-27 | The Johns Hopkins University | Methods and targets of dna methylation entropy |
| WO2024186778A1 (en) | 2023-03-03 | 2024-09-12 | Laboratory Corporation Of America Holdings | Methods and systems for positive cfdna screening on genetic variations using mosaicism ratio |
| CN116246704B (zh) * | 2023-05-10 | 2023-08-15 | 广州精科生物技术有限公司 | 用于胎儿无创产前检测的系统 |
| WO2024238593A1 (en) | 2023-05-15 | 2024-11-21 | Laboratory Corporation Of America Holdings | Machine-learning approaches to pan-cancer screening in whole genome sequencing |
| WO2025005860A1 (en) * | 2023-06-26 | 2025-01-02 | Johan Lindberg | Method of identifying and adjusting for systematic variability in dna abundance measurements |
| CN117230165A (zh) * | 2023-09-01 | 2023-12-15 | 深圳湾实验室 | 一种无创产前检测胎儿染色体拷贝数异常的优化方法 |
| KR102826451B1 (ko) * | 2023-09-01 | 2025-06-27 | 사회복지법인 삼성생명공익재단 | 신생아로부터 비침습적으로 분리된 검체를 이용한 신생아의 검체 분석 방법 |
| CN117237324B (zh) * | 2023-10-09 | 2024-03-29 | 苏州博致医疗科技有限公司 | 一种非侵入式整倍体预测方法及系统 |
Family Cites Families (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5720928A (en) | 1988-09-15 | 1998-02-24 | New York University | Image processing and analysis of individual nucleic acid molecules |
| US5075212A (en) | 1989-03-27 | 1991-12-24 | University Of Patents, Inc. | Methods of detecting picornaviruses in biological fluids and tissues |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5091652A (en) | 1990-01-12 | 1992-02-25 | The Regents Of The University Of California | Laser excited confocal microscope fluorescence scanner and method |
| US5432054A (en) | 1994-01-31 | 1995-07-11 | Applied Imaging | Method for separating rare cells from a population of cells |
| CA2157219C (en) | 1994-08-31 | 2010-10-05 | Munehiro Noda | Process for purifying recombinant human serum albumin |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| CA2207952A1 (en) | 1994-12-23 | 1996-07-04 | David Thornley | Automated dna sequencing |
| US5795782A (en) | 1995-03-17 | 1998-08-18 | President & Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
| US5670325A (en) | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
| CA2253710A1 (en) | 1996-04-25 | 1997-10-30 | Spectrametrix Inc. | Analyte assay using particulate labels |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5928870A (en) | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6100029A (en) | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
| US6300077B1 (en) | 1996-08-14 | 2001-10-09 | Exact Sciences Corporation | Methods for the detection of nucleic acids |
| US6403311B1 (en) | 1997-02-12 | 2002-06-11 | Us Genomics | Methods of analyzing polymers using ordered label strategies |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6566101B1 (en) | 1997-06-16 | 2003-05-20 | Anthony P. Shuber | Primer extension methods for detecting nucleic acids |
| US6570001B1 (en) | 1997-06-20 | 2003-05-27 | Institut Pasteur | Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds |
| EP1105529B2 (en) | 1998-07-30 | 2013-05-29 | Illumina Cambridge Limited | Arrayed biomolecules and their use in sequencing |
| US6263286B1 (en) | 1998-08-13 | 2001-07-17 | U.S. Genomics, Inc. | Methods of analyzing polymers using a spatial network of fluorophores and fluorescence resonance energy transfer |
| US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
| US20050287592A1 (en) | 2000-08-29 | 2005-12-29 | Yeda Research And Development Co. Ltd. | Template-dependent nucleic acid polymerization using oligonucleotide triphosphates building blocks |
| EP1218543A2 (en) | 1999-09-29 | 2002-07-03 | Solexa Ltd. | Polynucleotide sequencing |
| DE60027040T2 (de) | 1999-10-29 | 2006-11-23 | Stratagene California, La Jolla | Zusammensetzungen und methoden zur verwendung von dna polymerasen |
| US20010049102A1 (en) | 2000-02-24 | 2001-12-06 | Huang Xiaohua C. | Methods for determining single nucleotide variations |
| US6664056B2 (en) | 2000-10-17 | 2003-12-16 | The Chinese University Of Hong Kong | Non-invasive prenatal monitoring |
| AU2002239284A1 (en) * | 2000-11-27 | 2002-06-03 | The Regents Of The University Of California | Methods and devices for characterizing duplex nucleic acid molecules |
| DE10112515B4 (de) | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| CA2440754A1 (en) | 2001-03-12 | 2002-09-19 | Stephen Quake | Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension |
| WO2003000920A2 (en) | 2001-06-21 | 2003-01-03 | President And Fellows Of Harvard College | Methods for characterization of nucleic acid molecules |
| US6927028B2 (en) | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
| US20030157489A1 (en) | 2002-01-11 | 2003-08-21 | Michael Wall | Recursive categorical sequence assembly |
| CA2476835A1 (en) | 2002-02-20 | 2003-08-28 | University Of Virginia Patent Foundation | A non-invasive diagnostic test utilizing histone modification markers |
| US6977162B2 (en) | 2002-03-01 | 2005-12-20 | Ravgen, Inc. | Rapid analysis of variations in a genome |
| DE60310697D1 (de) | 2002-03-15 | 2007-02-08 | Epigenomics Ag | Entdeckungs- und diagnoseverfahren mit 5-methylcytosin-dna-glycosylase |
| US20040110208A1 (en) | 2002-03-26 | 2004-06-10 | Selena Chan | Methods and device for DNA sequencing using surface enhanced Raman scattering (SERS) |
| US7744816B2 (en) | 2002-05-01 | 2010-06-29 | Intel Corporation | Methods and device for biomolecule characterization |
| US20050019784A1 (en) | 2002-05-20 | 2005-01-27 | Xing Su | Method and apparatus for nucleic acid sequencing and identification |
| US7005264B2 (en) | 2002-05-20 | 2006-02-28 | Intel Corporation | Method and apparatus for nucleic acid sequencing and identification |
| US6952651B2 (en) | 2002-06-17 | 2005-10-04 | Intel Corporation | Methods and apparatus for nucleic acid sequencing by signal stretching and data integration |
| CA2497988C (en) | 2002-09-06 | 2011-03-29 | The Trustees Of Boston University | Quantification of gene expression |
| US7820378B2 (en) | 2002-11-27 | 2010-10-26 | Sequenom, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| WO2005010145A2 (en) | 2003-07-05 | 2005-02-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| US20070026406A1 (en) * | 2003-08-13 | 2007-02-01 | Iconix Pharmaceuticals, Inc. | Apparatus and method for classifying multi-dimensional biological data |
| US7846738B2 (en) | 2003-08-15 | 2010-12-07 | President And Fellows Of Harvard College | Study of polymer molecules and conformations with a nanopore |
| AU2004270220B2 (en) | 2003-09-05 | 2009-03-05 | The Chinese University Of Hong Kong | Method for non-invasive prenatal diagnosis |
| ATE435301T1 (de) | 2003-10-16 | 2009-07-15 | Sequenom Inc | Nicht invasiver nachweis fötaler genetischer merkmale |
| US20050095599A1 (en) | 2003-10-30 | 2005-05-05 | Pittaro Richard J. | Detection and identification of biopolymers using fluorescence quenching |
| US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
| US20050147980A1 (en) | 2003-12-30 | 2005-07-07 | Intel Corporation | Nucleic acid sequencing by Raman monitoring of uptake of nucleotides during molecular replication |
| US20100216151A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
| US20100216153A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
| US20060046258A1 (en) | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
| US7279337B2 (en) | 2004-03-10 | 2007-10-09 | Agilent Technologies, Inc. | Method and apparatus for sequencing polymers through tunneling conductance variation detection |
| WO2006028508A2 (en) | 2004-03-23 | 2006-03-16 | President And Fellows Of Harvard College | Methods and apparatus for characterizing polynucleotides |
| EP1784754A4 (en) | 2004-08-13 | 2009-05-27 | Harvard College | OPTI-NANOPORE DNA READING PLATFORM WITH ULTRAHOLE THROUGHPUT |
| AU2005308918B2 (en) | 2004-11-29 | 2012-09-27 | Sequenom, Inc. | Means and methods for detecting methylated DNA |
| US7645576B2 (en) | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
| EP3599609A1 (en) * | 2005-11-26 | 2020-01-29 | Natera, Inc. | System and method for cleaning noisy genetic data and using data to make predictions |
| US7960105B2 (en) | 2005-11-29 | 2011-06-14 | National Institutes Of Health | Method of DNA analysis using micro/nanochannel |
| TR201910868T4 (tr) | 2006-02-02 | 2019-08-21 | Univ Leland Stanford Junior | Dijital analizle invazif olmayan fetal genetik tarama. |
| WO2007100911A2 (en) | 2006-02-28 | 2007-09-07 | University Of Louisville Research Foundation | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
| TW200741192A (en) | 2006-03-10 | 2007-11-01 | Koninkl Philips Electronics Nv | Methods and systems for identification of DNA patterns through spectral analysis |
| WO2007121276A2 (en) | 2006-04-12 | 2007-10-25 | Biocept, Inc. | Enrichment of circulating fetal dna |
| US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
| US20090075252A1 (en) | 2006-04-14 | 2009-03-19 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
| WO2007140417A2 (en) | 2006-05-31 | 2007-12-06 | Sequenom, Inc. | Methods and compositions for the extraction and amplification of nucleic acid from a sample |
| EP2029779A4 (en) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| AU2007260750A1 (en) | 2006-06-16 | 2007-12-21 | Sequenom, Inc. | Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample |
| US20080081330A1 (en) | 2006-09-28 | 2008-04-03 | Helicos Biosciences Corporation | Method and devices for analyzing small RNA molecules |
| EP2081442B1 (en) | 2006-10-10 | 2016-08-10 | TrovaGene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| EP1944273A1 (en) | 2007-01-15 | 2008-07-16 | Rockwool International A/S | Process and apparatus for making mineral fibers |
| US8003319B2 (en) | 2007-02-02 | 2011-08-23 | International Business Machines Corporation | Systems and methods for controlling position of charged polymer inside nanopore |
| US8722327B2 (en) | 2007-03-28 | 2014-05-13 | Bionano Genomics, Inc. | Methods of macromolecular analysis using nanochannel arrays |
| AU2008236694B2 (en) | 2007-04-04 | 2014-01-23 | The Regents Of The University Of California | Compositions, devices, systems, and methods for using a nanopore |
| GB0713143D0 (en) | 2007-07-06 | 2007-08-15 | Ucl Business Plc | Nucleic acid detection method |
| EP3892736A1 (en) | 2007-07-23 | 2021-10-13 | The Chinese University of Hong Kong | Determining a nucleic acid sequence imbalance |
| US12180549B2 (en) | 2007-07-23 | 2024-12-31 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using genomic sequencing |
| EP2195452B1 (en) | 2007-08-29 | 2012-03-14 | Sequenom, Inc. | Methods and compositions for universal size-specific polymerase chain reaction |
| WO2009032779A2 (en) | 2007-08-29 | 2009-03-12 | Sequenom, Inc. | Methods and compositions for the size-specific seperation of nucleic acid from a sample |
| WO2009046445A1 (en) | 2007-10-04 | 2009-04-09 | Halcyon Molecular | Sequencing nucleic acid polymers with electron microscopy |
| US7767400B2 (en) | 2008-02-03 | 2010-08-03 | Helicos Biosciences Corporation | Paired-end reads in sequencing by synthesis |
| EP2271772B1 (en) | 2008-03-11 | 2014-07-16 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
| CA2718137A1 (en) | 2008-03-26 | 2009-10-01 | Sequenom, Inc. | Restriction endonuclease enhanced polymorphic sequence detection |
| WO2011050147A1 (en) | 2009-10-21 | 2011-04-28 | Bionanomatrix, Inc . | Methods and related devices for single molecule whole genome analysis |
| US8628919B2 (en) | 2008-06-30 | 2014-01-14 | Bionano Genomics, Inc. | Methods and devices for single-molecule whole genome analysis |
| US20110229877A1 (en) | 2008-07-07 | 2011-09-22 | Oxford Nanopore Technologies Limited | Enzyme-pore constructs |
| US9447152B2 (en) | 2008-07-07 | 2016-09-20 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| AU2009293232B2 (en) | 2008-09-16 | 2015-05-14 | Sequenom Center For Molecular Medicine | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
| US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| HUE031848T2 (en) | 2008-09-20 | 2017-08-28 | Univ Leland Stanford Junior | Non-invasive diagnosis of fetal aneuploidy by sequencing |
| GB2483810B (en) | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
| WO2010056728A1 (en) | 2008-11-11 | 2010-05-20 | Helicos Biosciences Corporation | Nucleic acid encoding for multiplex analysis |
| JP5846703B2 (ja) | 2008-11-18 | 2016-01-20 | バイオナノ ジェノミックス、インク． | ポリヌクレオチドのマッピング及び配列決定 |
| WO2010065470A2 (en) | 2008-12-01 | 2010-06-10 | Consumer Genetics, Inc. | Compositions and methods for detecting background male dna during fetal sex determination |
| CA2748030A1 (en) | 2008-12-22 | 2010-07-01 | Arnold R. Oliphant | Methods and genotyping panels for detecting alleles, genomes, and transcriptomes |
| US8455260B2 (en) | 2009-03-27 | 2013-06-04 | Massachusetts Institute Of Technology | Tagged-fragment map assembly |
| EP3211095B1 (en) | 2009-04-03 | 2019-01-02 | Sequenom, Inc. | Nucleic acid preparation compositions and methods |
| US8246799B2 (en) | 2009-05-28 | 2012-08-21 | Nabsys, Inc. | Devices and methods for analyzing biomolecules and probes bound thereto |
| US20100330557A1 (en) | 2009-06-30 | 2010-12-30 | Zohar Yakhini | Genomic coordinate system |
| US9725315B2 (en) | 2009-09-28 | 2017-08-08 | Bionano Genomics, Inc. | Nanochannel arrays and near-field illumination devices for polymer analysis and related methods |
| HUE061110T2 (hu) | 2009-11-05 | 2023-05-28 | Univ Hong Kong Chinese | Magzati genomelemzés anyai biológiai mintából |
| EP2516680B1 (en) | 2009-12-22 | 2016-04-06 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
| US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
| EP4074838A1 (en) | 2010-01-19 | 2022-10-19 | Verinata Health, Inc. | Novel protocol for preparing sequencing libraries |
| US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US20120270739A1 (en) | 2010-01-19 | 2012-10-25 | Verinata Health, Inc. | Method for sample analysis of aneuploidies in maternal samples |
| US10662474B2 (en) | 2010-01-19 | 2020-05-26 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing |
| US9260745B2 (en) * | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
| EP2526415B1 (en) | 2010-01-19 | 2017-05-03 | Verinata Health, Inc | Partition defined detection methods |
| US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
| WO2011143659A2 (en) | 2010-05-14 | 2011-11-17 | Fluidigm Corporation | Nucleic acid isolation methods |
| CA3207599A1 (en) | 2010-05-18 | 2011-11-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| WO2012006291A2 (en) | 2010-07-06 | 2012-01-12 | Life Technologies Corporation | Systems and methods to detect copy number variation |
| WO2012012703A2 (en) | 2010-07-23 | 2012-01-26 | Esoterix Genetic Laboratories, Llc | Identification of differentially represented fetal or maternal genomic regions and uses thereof |
| US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
| US8700338B2 (en) * | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
| SG190344A1 (en) | 2010-11-30 | 2013-06-28 | Univ Hong Kong Chinese | Detection of genetic or molecular aberrations associated with cancer |
| US20150064695A1 (en) | 2010-12-17 | 2015-03-05 | Celula Inc. | Methods for screening and diagnosing genetic conditions |
| BR112013016193B1 (pt) | 2010-12-22 | 2019-10-22 | Natera Inc | método ex vivo para determinar se um suposto pai é o pai biológico de um feto que está em gestação em uma gestante e relatório |
| EP2655666A2 (en) | 2010-12-23 | 2013-10-30 | Sequenom, Inc. | Fetal genetic variation detection |
| WO2012103031A2 (en) | 2011-01-25 | 2012-08-02 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
| BR112013020220B1 (pt) | 2011-02-09 | 2020-03-17 | Natera, Inc. | Método para determinar o estado de ploidia de um cromossomo em um feto em gestação |
| WO2012118745A1 (en) | 2011-02-28 | 2012-09-07 | Arnold Oliphant | Assay systems for detection of aneuploidy and sex determination |
| LT3567124T (lt) | 2011-04-12 | 2022-04-11 | Verinata Health, Inc. | Genominių frakcijų paskirstymas, naudojant polimorfizmo skaičiavimo rezultatus |
| GB2484764B (en) | 2011-04-14 | 2012-09-05 | Verinata Health Inc | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
| WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
| US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| PL2716766T3 (pl) | 2011-05-31 | 2017-09-29 | Berry Genomics Co., Ltd. | Urządzenie do wykrywania liczby kopii chromosomów płodowych lub chromosomów komórek nowotworowych |
| US20140235474A1 (en) | 2011-06-24 | 2014-08-21 | Sequenom, Inc. | Methods and processes for non invasive assessment of a genetic variation |
| KR101489568B1 (ko) | 2011-06-29 | 2015-02-03 | 비지아이 헬스 서비스 코포레이션 리미티드 | 태아 유전학적 이상의 비침습성 검출 |
| US9139874B2 (en) | 2011-07-07 | 2015-09-22 | Life Technologies Corporation | Bi-directional sequencing compositions and methods |
| US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
| US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| JP6073902B2 (ja) * | 2011-10-06 | 2017-02-01 | セクエノム， インコーポレイテッド | 遺伝的変異の非侵襲的評価のための方法およびプロセス |
| US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2850785C (en) | 2011-10-06 | 2022-12-13 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US8688388B2 (en) | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| DK2766496T3 (en) | 2011-10-11 | 2017-05-15 | Sequenom Inc | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS |
| CA2861856C (en) | 2012-01-20 | 2020-06-02 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
| US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
| EP3573066B1 (en) | 2012-03-13 | 2023-09-27 | The Chinese University Of Hong Kong | Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| ES2902401T3 (es) | 2012-05-21 | 2022-03-28 | Sequenom Inc | Métodos y procesos para la evaluación no invasiva de variaciones genéticas |
| US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| KR102393608B1 (ko) | 2012-09-04 | 2022-05-03 | 가던트 헬쓰, 인크. | 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법 |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| AU2013326980B2 (en) | 2012-10-04 | 2019-08-15 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20130309666A1 (en) | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3409791B1 (en) | 2013-03-15 | 2021-06-30 | Verinata Health, Inc. | Generating cell-free dna libraries directly from blood |
| EP4187543A1 (en) | 2013-04-03 | 2023-05-31 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2014190286A2 (en) | 2013-05-24 | 2014-11-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3011051B1 (en) | 2013-06-21 | 2019-01-30 | Sequenom, Inc. | Method for non-invasive assessment of genetic variations |
| GB201318369D0 (en) * | 2013-10-17 | 2013-12-04 | Univ Leuven Kath | Methods using BAF |
| US10174375B2 (en) | 2013-09-20 | 2019-01-08 | The Chinese University Of Hong Kong | Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases |
| BR112016007401B1 (pt) | 2013-10-04 | 2023-04-11 | Sequenom, Inc. | Método para determinar a presença ou ausência de uma aneuploidia cromossômica em uma amostra |
| EP3495496B1 (en) | 2013-10-07 | 2020-11-25 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
| GB201319779D0 (en) * | 2013-11-08 | 2013-12-25 | Cartagenia N V | Genetic analysis method |
| US20150347676A1 (en) | 2014-05-30 | 2015-12-03 | Sequenom, Inc. | Chromosome representation determinations |
| WO2016019042A1 (en) | 2014-07-30 | 2016-02-04 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3491560A1 (en) | 2016-07-27 | 2019-06-05 | Sequenom, Inc. | Genetic copy number alteration classifications |
| CA3207879A1 (en) | 2017-01-24 | 2018-08-02 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
-
2014
- 2014-05-23 WO PCT/US2014/039389 patent/WO2014190286A2/en not_active Ceased
- 2014-05-23 AU AU2014268377A patent/AU2014268377B2/en active Active
- 2014-05-23 KR KR1020237018438A patent/KR102665592B1/ko active Active
- 2014-05-23 IL IL300163A patent/IL300163B2/en unknown
- 2014-05-23 EP EP25182620.2A patent/EP4604127A3/en active Pending
- 2014-05-23 CN CN202011163273.XA patent/CN112575075B/zh active Active
- 2014-05-23 CA CA3189752A patent/CA3189752A1/en active Pending
- 2014-05-23 JP JP2016515122A patent/JP6561046B2/ja active Active
- 2014-05-23 KR KR1020227011344A patent/KR102540202B1/ko active Active
- 2014-05-23 EP EP19169503.0A patent/EP3578670B1/en active Active
- 2014-05-23 KR KR1020247015232A patent/KR20240068794A/ko active Pending
- 2014-05-23 US US14/892,782 patent/US10699800B2/en active Active
- 2014-05-23 EP EP14733818.0A patent/EP3004383B1/en active Active
- 2014-05-23 CA CA2910205A patent/CA2910205C/en active Active
- 2014-05-23 IL IL309903A patent/IL309903A/en unknown
- 2014-05-23 KR KR1020157036695A patent/KR102385062B1/ko active Active
- 2014-05-23 CN CN201480042105.1A patent/CN105555968B/zh active Active
-
2015
- 2015-10-20 IL IL24217615A patent/IL242176B/en active IP Right Grant
-
2018
- 2018-07-23 JP JP2018137542A patent/JP6749972B2/ja active Active
-
2019
- 2019-09-23 IL IL269567A patent/IL269567B2/en unknown
-
2020
- 2020-04-29 US US16/862,324 patent/US11462298B2/en active Active
- 2020-10-29 AU AU2020260501A patent/AU2020260501B2/en active Active
-
2022
- 2022-07-21 US US17/870,178 patent/US20220415435A1/en active Pending
-
2023
- 2023-08-02 AU AU2023210582A patent/AU2023210582A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020260501B2 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| US20210174894A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| EP3204512B1 (en) | Methods for partitioning of genomic sequences | |
| EP3760739B1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| EP3053071B1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| US20180327844A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK40124074A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK40092686A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK40013211B (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK40013211A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1217033B (en) | Methods for non-invasive assessment of genetic variations using area-under-curve (auc) analysis | |
| HK1218173B (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1234787A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1234787B (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1228033A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1228033B (en) | Methods and processes for non-invasive assessment of genetic variations | |
| HK1228033A1 (en) | Methods and processes for non-invasive assessment of genetic variations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230214 |
|
| EEER | Examination request |
Effective date: 20230214 |
|
| EEER | Examination request |
Effective date: 20230214 |
|
| EEER | Examination request |
Effective date: 20230214 |